BRCA1 and cancer: The usage of PARPi, which predominantly blocks the activity of PARP1, PARP2 and PARP3, is a well-established example of synthetic lethality-based therapy in BRCA1/2-mutated cancers with a limited toxicity towards normal cells and tissues [12,13,14,15].